Table 1.
Baseline patient characteristics
| Ig | Oral antibiotics | |
|---|---|---|
| n | 21 | 42 |
| Age, mean (SD), y | 71.2 (8.6) | 69.1 (7.8) |
| Female, n (%) | 13 (62%) | 21 (50%) |
| BMI, mean (SD), kg/m2 | 30.3 (7.5) | 28.8 (5.8) |
| IgG, mean (SD), g/L | 5.6 (5.3) | 5.3 (5.5) |
| Diagnosis, n (%) | ||
| CLL | 8 (38%) | 21 (50%) |
| MM | 3 (14%) | 9 (21%) |
| NHL | 8 (38%) | 12 (29%) |
| Other | 2 (10%) | 0 (0%) |
| Disease stage, n (%) | ||
| Treatment-naïve | 4 (19%) | 13 (32%) |
| Remission after treatment | 8 (38%) | 13 (32%) |
| Relapsed/refractory | 3 (14%) | 5 (12%) |
| Currently receiving treatment | 6 (29%) | 9 (22%) |
| Stable disease posttreatment | 0 (0%) | 1 (2%) |
| ECOG performance status, n (%) | ||
| 0 | 8 (38%) | 19 (46%) |
| 1 | 11 (52%) | 15 (37%) |
| 2 | 2 (10%) | 7 (17%) |
| Prior cancer treatments∗, n (%) | ||
| 0 | 4 (19%) | 12 (31%) |
| 1 | 6 (29%) | 11 (28%) |
| 2 | 5 (24%) | 5 (13%) |
| 3 | 4 (19%) | 6 (15%) |
| ≥4 | 2 (10%) | 5 (13%) |
| Prior ASCT, n (%) | ||
| No | 18 (86%) | 37 (88%) |
| Yes | 3 (14%) | 5 (12%) |
| Infections requiring antibiotics in the past year, mean (SD) | 2.5 (1.8) | 2.8 (1.9) |
| Infections requiring hospitalization in the past year, mean (SD) | 0.4 (0.8) | 0.7 (1.1) |
ASCT, autologous stem cell transplant; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
∗
Including cancer treatments for other prior malignancies.